Transfer of the CYP4A region of chromosome 5 from Lewis to Dahl S rats attenuates renal injury

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 6, 2008, Pages

  Williams, Jan Michael ^a   Sarkis, Albert ^a   Hoagland, Kimberly M ^a   Fredrich, Katherine ^a   Ryan, Robert P ^a   Moreno, Carol ^a   Lopez, Bernardo ^a   Lazar, Jozef ^a   Fenoy, Francisco J ^b   Sharma, Mukut ^a   Garrett, Michael R ^a   Jacob, Howard J ^a   Roman, Richard J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

20 hydroxyeicosatetraenoic acid; Dahl salt sensitive rats; Dihydroxyeicosatrienoic acids; Epoxyeicosatrienoic acids; Glomerulosclerosis; Glomerulus; Hypertension; Kidney; Rattus norvegicus 5; Renal hemodynamics; Transforming growth factor

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; CYTOCHROME P450 4A; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ARTICLE; CAPILLARY PRESSURE; CHROMOSOME 5; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HYPERTENSION; KIDNEY DISEASE; KIDNEY INJURY; LEWIS RAT; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION;

EID: 57349191137     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90525.2008     Document Type: Article

References (43)

1. Alonso-Galicia M, Frohlich B, Roman RJ. Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. Hypertension 31: 232-236, 1998.
2. Alonso-Galicia M, Maier KG, Greene AS, Cowley AW Jr, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol 283: R60-R68, 2002.
3. Chen PY, St John PL, Kirk KA, Abrahamson DR, Sanders PW. Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 68: 174-184, 1993.
4. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ. Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 283: R757-R767, 2002.
5. Dahly-Vernon AJ, Sharma M, McCarthy ET, Savin VJ, Ledbetter SR, Roman RJ. Transforming growth factor-beta, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension 45: 643-648, 2005.
6. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 111: 63-69, 2005.
7. Garrett MR, Dene H, Walder R, Zhang QY, Cicila GT, Assadnia S, Deng AY, Rapp JP. Genome scan and congenic strains for blood pressure QTL using Dahl salt-sensitive rats. Genome Res 8: 711-723, 1998.
8. Garrett MR, Rapp JP. Two closely linked interactive blood pressure QTL on rat chromosome 5 defined using congenic Dahl rats. Physiol Genomics 8: 81-86, 2002.
9. Hoagland KM, Flasch AK, Dahly-Vernon AJ, dos Santos EA, Knepper MA, Roman RJ. Elevated BSC-1 and ROMK expression in Dahl saltsensitive rat kidneys. Hypertension 43: 860-865, 2004.
10. Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 42: 669-673, 2003.
11. Hoagland KM, Maier KG, Roman RJ. Contributions of 20-HETE to the antihypertensive effects of Tempol in Dahl salt-sensitive rats. Hypertension 41: 697-702, 2003.
12. Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 98: 5211-5216, 2001.
13. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 104: 751-760, 1999.
14. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol Regul Integr Comp Physiol 270: R217-R227, 1996.
15. Ito O, Roman RJ. Role of 20-HETE in elevating chloride transport in the thick ascending limb of Dahl SS/Jr rats. Hypertension 33: 419-423, 1999.
16. Laffer CL, Gainer JV, Waterman MR, Capdevila JH, Laniado-Schwartzman M, Nasjletti A, Brown NJ, Elijovich F. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 51: 767-772, 2008.
17. Ma YH, Schwartzman ML, Roman RJ. Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 267: R579-R589, 1994.
18. Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A, Holmer S, Hengstenberg C, Doering A, Loewel H, Hense HW, Schunkert H, Erdmann J. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 46: 766-771, 2005.
19. Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P, Pomarino A, Holmer S, Hengstenberg C, Doering A, Loewel H, Hense HW, Ziegler A, Erdmann J, Schunkert H. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 24: 1965-1970, 2006.
20. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 12: 285-290, 1988.
21. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 95: 12701-12706, 1998.
22. Nakagawa K, Holla VR, Wei Y, Wang WH, Gatica A, Wei S, Mei S, Miller CM, Cha DR, Price E Jr, Zent R, Pozzi A, Breyer MD, Guan Y, Falck JR, Waterman MR, Capdevila JH. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 116: 1696-1702, 2006.
23. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomerular injury in Dahl saltsensitive rats. Hypertension 20: 651-658, 1992.
24. Parmentier JH, Muthalif MM, Nishimoto AT, Malik KU. 20-Hydroxyeicosatetraenoic acid mediates angiotensin ii-induced phospholipase d activation in vascular smooth muscle cells. Hypertension 37: 623-629, 2001.
25. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26: 137-143, 1984.
26. Raij L, Chiou XC, Owens R, Wrigley B. Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model. Am J Med 79: 37-41, 1985.
27. Roman RJ, Alonso-Galicia M, Wilson TW. Renal P450 metabolites of arachidonic acid and the development of hypertension in Dahl salt-sensitive rats. Am J Hypertens 10: 63S-67S, 1997.
28. Roman RJ, Hoagland KM, Lopez B, Kwitek AE, Garrett MR, Rapp JP, Lazar J, Jacob HJ, Sarkis A. Characterization of blood pressure and renal function in chromosome 5 congenic strains of Dahl S rats. Am J Physiol Renal Physiol 290: F1463-F1471, 2006.
29. Roman RJ, Ma YH, Frohlich B, Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 21: 985-988, 1993.
30. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 306: 1276-1279, 1982.
31. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol 287: C517-C526, 2004.
32. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3: 1260-1269, 1992.
33. Sharma R, Khanna A, Sharma M, Savin VJ. Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 58: 131-136, 2000.
34. Shatara RK, Quest DW, Wilson TW. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol 78: 367-371, 2000.
35. Stec DE, Mattson DL, Roman RJ. Inhibition of renal outer medullary 20-HETE production produces hypertension in Lewis rats. Hypertension 29: 315-319, 1997.
36. Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M. Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 7: 2578-2589, 1996.
37. Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis 13: 485-493, 1989.
38. Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 16: 452-461, 1990.
39. Van Dokkum RP, Sun CW, Provoost AP, Jacob HJ, Roman RJ. Altered renal hemodynamics and impaired myogenic responses in the fawn-hooded rat. Am J Physiol Regul Integr Comp Physiol 276: R855-R863, 1999.
40. Williams JM, Sharma M, Anjaiahh S, Falck JR, Roman RJ. Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier. Am J Physiol Renal Physiol 293: F501-F505, 2007.
41. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 31: 225-231, 1998.
42. Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, Roman RJ. Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol Renal Fluid Electrolyte Physiol 266: F275-F282, 1994.
43. Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ. Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol Renal Fluid Electrolyte Physiol 266: F934-F941, 1994.